中国学者发现一种微核糖核酸高表达与三阴性乳腺癌不良预后相关
既往研究已经报道微核糖核酸-454（miR-454）在大多数癌症中发挥引起肿瘤或抑制肿瘤的作用，然而miR-454在乳腺癌中的临床意义尚不明确。
2016年8月31日，美国《肿瘤标靶》在线发表复旦大学附属肿瘤医院上海市乳腺癌重点实验室、福建医科大学附属协和医院的回顾性与前瞻性研究报告，采用原位杂交（ISH）分析了534例复旦大学附属肿瘤医院女性患者乳腺癌标本组织微阵列miR-454表达。
微阵列又称芯片，是从一般阵列发展而来的点阵密度极高的阵列，包括基因、蛋白质、细胞和组织等微阵列，将许多核酸片段、多肽、蛋白质或组织、细胞等生物标本有序地固化在惰性载体（玻片、硅片、尼龙膜等）表面，组成高度密集二维阵列的微型生化反应和分析系统。
该研究将250例患者分入训练集（回顾性演算组），其余284例分入验证集（前瞻性验算组），通过卡普兰-迈耶法分析miR-454与临床结局之间的关系。
结果发现，miR-454高表达在两个队列中均与无病生存（DFS）较差有相关性（演算组225例，P=0.006；验算组241例，P=0.010）。
而且，在三阴性乳腺癌亚型中，miR-454与较差的临床结局呈正相关（演算组92例，P=0.013；验算组116例，P=0.014）。
此外，三阴性乳腺癌亚型患者对蒽环类的效果显著优于非蒽环类化疗（P=0.042），但是在总体、高、低miR-454表达队列中未见显著优势（P=0.161、0.253、0.056）。
因此，该研究结果表明miR-454对于三阴性乳腺癌可能成为预后和化疗效果的预测指标。
Oncotarget. 2016 Aug 31. [Epub ahead of print]
High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
Cao ZG, Li JJ, Yao L, Huang YN, Liu YR, Hu X, Song CG, Shao ZM.
Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, China; Affiliated Union Hospital, Fujian Medical University, Fuzhou, China.
MicroRNA-454 (miR-454) has been reported to play an oncogenic or tumor suppressor role in most cancers. However, the clinical relevance of miR-454 in breast cancer remains unclear. We examined the expression of miR-454 in a tissue microarray containing 534 breast cancer specimens from female patients at Fudan University Shanghai Cancer Center using in situ hybridization (ISH). Of these, 250 patients formed the training set and the other 284 were the validation set. The relationship between miR-454 and clinical outcome was analyzed by the Kaplan-Meier method. High expression of miR-454 indicated worse disease-free survival (DFS) in both cohorts (P = 0.006 for training set; P = 0.010 for validation set). Furthermore, in the triple-negative breast cancer (TNBC) subtype, miR-454 was positively correlated with worse clinical outcome (P = 0.013 for training set, P = 0.014 for validation set). In addition, patients in the low miR-454 expression cohort had better response to anthracycline compared to non-anthracycline chemotherapy (P = 0.056), but this difference was not observed in the high miR-454 expression cohort. Our findings indicated that miR-454 is a potential predictor of prognosis and chemotherapy response in TNBC.
KEYWORDS: chemotherapy; disease-free survival; in situ hybridization; microRNA-454; triple-negative breast cancer
PMID: 27588500
DOI: 10.18632/oncotarget.11764